News Sentiment

KYMR sentiment intelligence

Kymera Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 119.35 Week of 10 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

86/100 classification confidence.

Company focus 56

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+5.1% over one week, +38.4% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 86/100 classification
One-week reaction 5.1% Price confirming higher
Trend fit Trend active 38.4% over four weeks
Fair value 155.9% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 35
Negative 14

Relevance

Why the article matched

Direct first
Direct company coverage 56
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
Moomoo 7
MT Newswires 4
Quartr 3
Simply Wall Street 3
Investing.com Canada 3
timothysykes.com 3
simplywall.st 3

Event Lens

What the news is about

Classified themes
Market update 45
Earnings 11
Analyst action 7
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 64
GuruFocus Direct company coverage

Insider Sell: Noah Goodman Sells Shares of Kymera Therapeutics Inc (KYMR)

Noah Goodman, Chief Business Officer at Kymera Therapeutics Inc, sold 3,389 shares of the company on July 1, 2026. This sale follows a pattern of 45 insider sells against only 1 insider buy over the past year. The stock is currently trading at $114.29, which is significantly over

Tone
Negative 29/100
Event
Market update
Published
03 Jul 2026 00:09
Source
GuruFocus
Market source Direct company coverage

KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug

Kymera Therapeutics (KYMR) stock has risen 50.9% year-to-date due to strong investor optimism surrounding its lead drug candidate, KT-621, for atopic dermatitis and asthma. The company recently completed enrollment for its phase IIb BROADEN2 study ahead of schedule, with pivotal

Tone
Positive 75/100
Event
Market update
Published
02 Jul 2026 15:40
Source
Market source
Investing.com Canada Direct company coverage

Form 144 Kymera Therapeutics For: 2 July By Investing.com

This article announces the filing of Form 144 for Kymera Therapeutics (KYMR) on July 2nd, without providing further details on the content of the filing. It is presented within a news aggregator format by Investing.com, surrounded by various market data and other news headlines.

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 12:40
Source
Investing.com Canada
Moomoo Direct company coverage

Kymera Therapeutics(KYMR.US) Director Sells US$59.88 Million in Common Stock

A director at Kymera Therapeutics (KYMR.US) has recently sold common stock valued at US$59.88 million. This significant insider transaction indicates a major change in the director's holdings in the company. Further details regarding the transaction would be available in the offi

Tone
Negative 19/100
Event
Market update
Published
01 Jul 2026 14:40
Source
Moomoo